Noelle K. LoConte, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. LoConte is an associate professor of medicine at the University of Wisconsin. She completed medical school at the University of Illinois at Chicago, then did her internship in internal medicine at UW. Dr. LoConte completed her internal medicine residency at Oregon Health Sciences University in Portland. She has also completed fellowship training in both medical oncology as well as geriatrics. She joined the faculty of the UW Carbone Cancer Center in the summer of 2006. She is the recipient of the American Society of Clinical Oncology Young Investigator Award for 2006, and has funding from the Centers for Disease Control and the National Cancer Institute. She has been a principal investigator on many clinical trials of new chemotherapies for gastrointestinal cancers, from Phase I through Phase III studies. Dr. LoConte is also the co-leader of the UW Carbone Cancer Center gastrointestinal disease oriented working group. Dr. LoConte's clinical interests are in gastrointestinal cancers, including liver and pancreas cancers, as well as cancer of any type in the older adult.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of Wisconsin Hospital and Clinics, Madison, WI
Oregon Health Sciences University, Portland
University of Wisconsin Hospital and Clinics, Madison, WI
University of Illinois, Chicago, 2000
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. LoConte's research interests are in predictors of chemotherapy toxicity, as well as trials of chemotherapy in older adults and patients with gastrointestinal cancers.
Jin N Lubner SJ Mulkerin DL Rajguru S Carmichael L Chen H Holen KD LoConte NK .
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist. 2016 Jul;21(7):785-6
[PubMed ID: 27261467]
Katz MH Shi Q Ahmad SA Herman JM Marsh RW Collisson E Schwartz L Frankel W Martin R Conway W Truty M Kindler H Lowy AM Bekaii-Saab T Philip P Talamonti M Cardin D LoConte N Shen P Hoffman JP Venook AP .
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 Jun 8;:e161137
[PubMed ID: 27275632]
Deming DA Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Eickhoff JC Kolesar JM Fioravanti S Greten TF Compton K Doyle AG Wilding G Duffy A Liu G .
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs. 2016 Apr;34(2):168-75
[PubMed ID: 26666244]
Decker MR Trentham-Dietz A Loconte NK Neuman HB Smith MA Punglia RS Greenberg CC Wilke LG .
The Role of Intraoperative Pathologic Assessment in the Surgical Management of Ductal Carcinoma In Situ. Ann Surg Oncol. 2016 Mar 29;
[PubMed ID: 27026436]
Neuman HB Rathouz PJ Winslow E Weiss JM LoConte NK Lin CP Wurm M Smith MA Schrag D Greenberg CC .
Use of a novel statistical technique to examine the delivery of breast cancer follow-up care by different types of oncology providers. J Eval Clin Pract. 2016 Mar 17;
[PubMed ID: 26991311]
Ko AH LoConte N Tempero MA Walker EJ Kate Kelley R Lewis S Chang WC Kantoff E Vannier MW Catenacci DV Venook AP Kindler HL .
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5
[PubMed ID: 26390428]
Tran NH Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Clipson L Matkowskyj KA Deming DA .
Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015 Sep;7(5):252-62
[PubMed ID: 26327923]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK .
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol. 2015 Aug;76(2):317-23
[PubMed ID: 26068189]
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G .
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs. 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
LoConte NK Deming DA .
Mailed invitations for colorectal screening are effective in increasing screening participation in uninsured adults with faecal immunochemical testing: the preferred screening modality. Evid Based Med. 2014 Aug;19(4):145
[PubMed ID: 24727711]
Weiss JM Schumacher J Allen GO Neuman H Lange EO Loconte NK Greenberg CC Smith MA .
Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol. 2014 Jun;21(6):1781-91
[PubMed ID: 24643898]
Schmocker RK Caretta-Weyer H Weiss JM Ronk K Havlena J Loconte NK Decker M Smith MA Greenberg CC Neuman HB .
Determining breast cancer axillary surgery within the surveillance epidemiology and end results-Medicare database. J Surg Oncol. 2014 Jun;109(8):756-9
[PubMed ID: 24643795]
Neuman HB Weiss JM Schrag D Ronk K Havlena J LoConte NK Smith MA Greenberg CC .
Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors. Ann Surg Oncol. 2013 Dec;20(13):4128-36
[PubMed ID: 23943027]
LoConte NK Weeth-Feinstein L Conlon A Scott S .
Engaging health systems to increase colorectal cancer screening: community-clinical outreach in underserved areas of Wisconsin. Prev Chronic Dis. 2013 Nov 21;10:E192
[PubMed ID: 24262024]
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ .
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Neuman HB Weiss JM Leverson G O'Connor ES Greenblatt DY Loconte NK Greenberg CC Smith MA .
Predictors of short-term postoperative survival after elective colectomy in colon cancer patients ≥ 80 years of age. Ann Surg Oncol. 2013 May;20(5):1427-35
[PubMed ID: 23292483]
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Neuman HB O'Connor ES Weiss J Loconte NK Greenblatt DY Greenberg CC Smith MA .
Surgical treatment of colon cancer in patients aged 80 years and older : analysis of 31,574 patients in the SEER-Medicare database. Cancer. 2013 Feb 1;119(3):639-47
[PubMed ID: 22893570]
Weiss JM Pfau PR O'Connor ES King J LoConte N Kennedy G Smith MA .
Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011 Nov 20;29(33):4401-9
[PubMed ID: 21969498]
O'Connor ES Greenblatt DY LoConte NK Gangnon RE Liou JI Heise CP Smith MA .
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011 Sep 1;29(25):3381-8
[PubMed ID: 21788561]